Compare Hilton Hotels Corporation Common Stock (HLT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Tango Therapeutics Inc. — how do they compare? Hilton Hotels Corporation Common Stock trades at $329.1 (market cap $74.18B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 19.8× Tango Therapeutics Inc.'s market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 139 Days and Tango Therapeutics Inc. for 0 Days on average.
| HLT | TNGX | |
|---|---|---|
Market Cap | $74.18B | $3.75B |
Volume | 1,295,545 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $32.90 |
52-Week Low | $256.96 | $7.50 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $87.19B | $2.77B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $328.12, up 0.18% on the day, with strong technical momentum as the stock approaches resistance near $330. The company demonstrates solid fundamental performance with revenue growth from $12.04B in 2025 to projected $12.5B in 2026, consistently beating earnings expectations in recent quarters. Analyst sentiment remains bullish with 57% buy ratings and a $350 consensus price target, supported by institutional accumulation and positive travel industry trends.
HLT presents a compelling investment case with strong earnings momentum and global portfolio expansion, though elevated valuation metrics (P/E 48.4) and rising debt levels warrant caution. The stock's proximity to technical resistance and overbought RSI readings suggest potential near-term consolidation before further upside toward analyst targets. Key risks include macroeconomic sensitivity and competitive pressures in the hospitality sector.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
